Hutch News
Results per Page:
Fred Hutch at ASCO
Immunotherapy advances, insights into health economics and leadership awards dominate oncology gathering
Immunotherapy has long-term benefit for patients with advanced Merkel cell carcinoma
‘Incredibly big change’ in treatment of deadly skin cancer, new data show
At half the cost, Canadian colorectal cancer survival similar to that of U.S.
Cross-border collaboration compared findings in British Columbia and Washington state
Fred Hutch scientists to feature health economics, next-gen immunotherapy, health disparities and more at ASCO
The American Society of Clinical Oncology will hold its annual meeting June 1–5 in Chicago
President's Cancer Panel addresses cost of cancer drugs
Fred Hutch leaders helped shape recommendations that put patients first, promoting value, affordability, innovation
Surviving cancer without going broke
HICOR’s Value in Cancer Care Summit tackles skyrocketing costs, financial toxicity, balancing cost with the right care and more
With immunotherapy trial, ‘a real paradigm shift’ in rare skin cancer
Investigators report ‘extraordinarily’ long-lasting treatment responses in patients with chemo-resistant, metastatic Merkel cell carcinoma
Patients with advanced lymphoma in remission after T-cell therapy
New study: 7 of 11 trial participants who got two-drug combination chemo plus intermediate dose of engineered T cells went into complete remission
93 percent of advanced leukemia patients in remission after immunotherapy
‘Exciting’ but early results from trial of engineered immune cells
'Finally showing hope': Immunotherapy trial results transforming care for rare skin cancer
Immunotherapy trial results transforming care for rare skin cancer
Another health disparity: clinical trials
Low-income cancer patients are less likely to take part in clinical trials for new treatments, study shows